Gyre Therapeutics (GYRE) Invested Capital (2010 - 2014)
Gyre Therapeutics (GYRE) posted quarterly Invested Capital of $478000.0 for Q3 2014, down 45.25% year-over-year from $873000.0 in Q3 2013, and down 31.62% quarter-over-quarter from $699000.0 in Q2 2014.
Gyre Therapeutics (GYRE) Invested Capital (2010 - 2014) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Invested Capital for 5 consecutive years, with $478000.0 the latest figure, recorded in Q3 2014.
- In Q3 2014, Invested Capital fell 45.25% year-over-year to $478000.0; the TTM figure through Jun 2015 stood at $478000.0 (down 85.07% YoY), while the FY2013 annual figure was $853000.0, changed 0.24% from the prior year.
- Invested Capital eased to $478000.0 in Q3 2014 per GYRE's latest filing, from $699000.0 in the prior quarter.
- Across five years, Invested Capital topped out at $1.9 million in Q2 2011 and bottomed at $478000.0 in Q3 2014.
- Historically, Invested Capital has averaged $1.0 million across 5 years, with a median of $866000.0 in 2013.
- Annual changes were most pronounced in 2012 — Invested Capital tumbled 54.5% — and 2013, when it climbed 3.44%.
- Gyre Therapeutics' Invested Capital stood at $1.7 million in 2010, then declined by 27.43% to $1.2 million in 2011, then sank by 31.43% to $851000.0 in 2012, then gained by 0.24% to $853000.0 in 2013, then tumbled by 43.96% to $478000.0 in 2014.
- Business Quant data shows GYRE's Invested Capital at $478000.0 in Q3 2014, $699000.0 in Q2 2014, and $776000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 190.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 380.00 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 478,000.00 |
| Jun 30, 2014 | 699,000.00 |
| Mar 31, 2014 | 776,000.00 |
| Dec 31, 2013 | 853,000.00 |
| Sep 30, 2013 | 873,000.00 |
| Jun 30, 2013 | 866,000.00 |
| Mar 31, 2013 | 858,000.00 |
| Dec 31, 2012 | 851,000.00 |
| Sep 30, 2012 | 844,000.00 |
| Jun 30, 2012 | 870,000.00 |
| Mar 31, 2012 | 896,000.00 |
| Dec 31, 2011 | 1.24 Mn |
| Sep 30, 2011 | 1.59 Mn |
| Jun 30, 2011 | 1.91 Mn |
| Dec 31, 2010 | 1.71 Mn |